
The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.

The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.

Published: September 15th 2008 | Updated:

259 Prospect Plains Rd, Bldg H
 Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
